Barinthus price target lowered to $8 from $15 at H.C. Wainwright

H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Barinthus Biotherapeutics to $8 from $15 and keeps a Buy rating on the shares following the Q4 report. The price target better reflects the risk of developing a cure for infectious diseases, the analyst tells investors in a research note.